INMUNE BIO INC (INMB)

US45782T1051 - Common Stock

4.4  -0.02 (-0.45%)

After market: 4.4 0 (0%)

Fundamental Rating

3

Taking everything into account, INMB scores 3 out of 10 in our fundamental rating. INMB was compared to 568 industry peers in the Biotechnology industry. While INMB seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, INMB is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

INMB had negative earnings in the past year.
INMB had a negative operating cash flow in the past year.
In the past 5 years INMB always reported negative net income.
INMB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of INMB (-78.19%) is worse than 69.20% of its industry peers.
INMB has a Return On Equity of -106.71%. This is comparable to the rest of the industry: INMB outperforms 44.42% of its industry peers.
Industry RankSector Rank
ROA -78.19%
ROE -106.71%
ROIC N/A
ROA(3y)-38.79%
ROA(5y)-35.5%
ROE(3y)-53.97%
ROE(5y)-45.14%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INMB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

INMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INMB has about the same amount of shares outstanding.
The number of shares outstanding for INMB has been increased compared to 5 years ago.
Compared to 1 year ago, INMB has an improved debt to assets ratio.

2.2 Solvency

INMB has an Altman-Z score of -2.01. This is a bad value and indicates that INMB is not financially healthy and even has some risk of bankruptcy.
INMB has a Altman-Z score of -2.01. This is comparable to the rest of the industry: INMB outperforms 53.27% of its industry peers.
INMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.01
ROIC/WACCN/A
WACC12.08%

2.3 Liquidity

A Current Ratio of 2.59 indicates that INMB has no problem at all paying its short term obligations.
INMB has a Current ratio of 2.59. This is in the lower half of the industry: INMB underperforms 69.91% of its industry peers.
A Quick Ratio of 2.59 indicates that INMB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.59, INMB is doing worse than 68.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.59

More info and screens

6

3. Growth

3.1 Past

The earnings per share for INMB have decreased strongly by -43.42% in the last year.
The Revenue for INMB has decreased by -81.74% in the past year. This is quite bad
Measured over the past years, INMB shows a very strong growth in Revenue. The Revenue has been growing by 149.33% on average per year.
EPS 1Y (TTM)-43.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-81.74%
Revenue growth 3Y149.33%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

INMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.75% yearly.
INMB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 259.90% yearly.
EPS Next Y-40.17%
EPS Next 2Y-11.68%
EPS Next 3Y-4.34%
EPS Next 5Y15.75%
Revenue Next Year-92.14%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y259.9%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as INMB's earnings are expected to decrease with -4.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.68%
EPS Next 3Y-4.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INMB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMUNE BIO INC

NASDAQ:INMB (12/20/2024, 8:18:34 PM)

After market: 4.4 0 (0%)

4.4

-0.02 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/amc
Earnings (Next)N/A N/A
Inst Owners20.76%
Inst Owner Change31.85%
Ins Owners20.37%
Ins Owner Change0.51%
Market Cap97.55M
Analysts85
Price Target20.23 (359.77%)
Short Float %23.55%
Short Ratio17.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.88%
Min EPS beat(2)-18.44%
Max EPS beat(2)22.19%
EPS beat(4)1
Avg EPS beat(4)-3.19%
Min EPS beat(4)-18.44%
Max EPS beat(4)22.19%
EPS beat(8)3
Avg EPS beat(8)-206.28%
EPS beat(12)7
Avg EPS beat(12)-129.8%
EPS beat(16)8
Avg EPS beat(16)-102.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.06%
EPS NQ rev (1m)-3.7%
EPS NQ rev (3m)22.22%
EPS NY rev (1m)-2.91%
EPS NY rev (3m)-1.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-0.95%
Revenue NY rev (3m)-69.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2322.57
P/FCF N/A
P/OCF N/A
P/B 2.52
P/tB 4.4
EV/EBITDA N/A
EPS(TTM)-2.18
EYN/A
EPS(NY)-2.08
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.74
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.19%
ROE -106.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.79%
ROA(5y)-35.5%
ROE(3y)-53.97%
ROE(5y)-45.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.59
Quick Ratio 2.59
Altman-Z -2.01
F-Score2
WACC12.08%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-40.17%
EPS Next 2Y-11.68%
EPS Next 3Y-4.34%
EPS Next 5Y15.75%
Revenue 1Y (TTM)-81.74%
Revenue growth 3Y149.33%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-92.14%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y259.9%
EBIT growth 1Y-53.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.82%
OCF growth 3YN/A
OCF growth 5YN/A